An Off-the-Shelf Cell Therapy Goes Head-to-Head With CAR-T

For the small but significant group of rheumatoid arthritis patients who don't respond to biologics, even after trying several, options have historically run out fast. In the last couple of years, CAR T-cell therapy, originally developed for blood cancers, has generated real excitement as a possible answer for these refractory cases, since it can reset an overactive immune system rather than just dampening it. But CAR-T comes with real drawbacks: it requires collecting a patient's own cells, engineering them in a lab over several weeks, and carries meaningful risk of side effects like cytokine release syndrome and neurotoxicity.

Artiva Biotherapeutics is testing a different approach called AlloNK, a donor-derived (allogeneic) natural killer cell therapy given alongside rituximab, an antibody that helps deplete the immune system's B cells. Because AlloNK uses cells from healthy donors rather than the patient's own, it can be manufactured in advance and given essentially off-the-shelf, without the weeks of lead time CAR-T requires.

Data presented at the EULAR 2026 congress in June, and highlighted in a company announcement on June 8, showed a 71% ACR50 response rate (meaning patients saw at least a 50% improvement in core disease measures) at six months in a company-sponsored Phase 2a trial of patients with highly refractory rheumatoid arthritis, those who had already failed multiple biologic treatments. Just as notable, the therapy achieved deep B-cell depletion without the cytokine release syndrome or neurotoxicity that can accompany CAR-T, and it's given in an outpatient setting rather than requiring a hospital stay.

The FDA has taken note. The agency granted AlloNK Regenerative Medicine Advanced Therapy (RMAT) designation for refractory rheumatoid arthritis, a status meant to speed up development and give the company more frequent access to FDA guidance. Artiva says it's now cleared to move toward a single registrational Phase 3 trial testing AlloNK plus rituximab against rituximab alone, expected to start in the second half of 2026 and enroll around 150 patients. Early data in Sjogren's disease and systemic sclerosis was also presented at EULAR, suggesting the same approach may extend beyond RA.

It's still early. This is Phase 2a data in a relatively small, highly selected patient group, not yet the large randomized trial that would support an approval. But for patients who have run out of biologic options, a therapy that offers CAR-T-like depth of response without the manufacturing wait or the harshest side effects is a genuinely encouraging signal, and one worth discussing with your rheumatologist if you fall into that hard-to-treat group.